Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00088036
• Date of registration: 19/07/2004
• Prospective Registration: No
• Primary sponsor: Eli Lilly and Company
• Public title: Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder
• Scientific title: Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo
• Date of first enrolment: February 2004
• Target sample size: 450
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00088036
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
• Phase: Phase 3

Countries of recruitment

Argentina, Italy, Poland, Romania, Turkey, United States

Contacts

• Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
• Affiliation: Eli Lilly and Company

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients must be of outpatient status at Visit 1 and through Visit 2

- Patients must be 18 through 65 years of age at Visit 1

- Patients must meet all of the DSM-IV-TR General Diagnostic Criteria for a Personality
Disorder AND Patients must meet DSM-IV-TR diagnostic criteria for BPD as determined
by the DIPD-IV, confirmed by a psychiatrist with training in the evaluation and
assessment of BPD.

- The symptom severity as assessed by the total score of the ZAN-BPD, confirmed by a
psychiatrist with training in the evaluation and assessment of BPD, must be greater
than or equal to 9 at Visit 2.

- Female patients of childbearing potential must test negative for pregnancy and must
be using medically accepted means of contraception throughout the study. Use of any
oral or injectable contraception must be initiated prior to Visit 2.

Exclusion Criteria:

- Investigators, study site personnel directly affiliated with the study, or immediate
family of investigator site personnel directly affiliated with the study. Immediate
family is defined as a spouse, parent, child, or sibling, whether biological or
legally adopted.

- Persons employed by Lilly (that is, employees, temporary contract workers, or
designees responsible for the conduct of the study). Immediate family of Lilly
employees may participate in Lilly-sponsored clinical trials, but are not permitted
to participate at a Lilly facility. Immediate family is defined as a spouse, parent,
child, or sibling, whether biological or legally adopted

- Have previously participated (have been randomized) or withdrawn from this study or
any other Lilly sponsored study investigating olanzapine.

- Have had previous treatment with olanzapine unless, in the opinion of the
investigator, the patient's previous treatment was inadequate in dose or duration to
provide an accurate assessment of the therapy, or the effect of olanzapine was
confounded by concomitant medication.

- Female patients who are either pregnant or nursing.



Age minimum: 18 Years
Age maximum: 65 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Borderline Personality Disorder

Intervention(s)

Drug: Olanzapine

Primary Outcome(s)

To assess the efficacy of olanzapine therapy (5.0-10.0 mg/day) compared with placebo in patients with BPD,as defined by DSM-IV-TR criteria,

in improving overall symptomatology as measured by the last observation carried forward (LOCF) mean change from baseline to endpoint in the ZAN-BPD total score for up to 12 weeks of double-blind treatment.

Secondary Outcome(s)

(Self-mutilation is defined as deliberate physical self harm without the intent to commit suicide)

To assess the efficacy of olanzapine 2.5 mg/day compared with placebo in patients with BPD, as defined by DSM-IV-TR criteria

to assess the reduction of self-mutilation determined by the mean frequency of self-mutilation attempts as captured on the Lifetime Self-Destructiveness scale (LSDS), which will measure both frequency and nature of attempts

to assess the safety as measured by treatment-emergency adverse events (TEAE), change in vital signs and laboratory analytes, electrocardiograms and severity of any extrapyramidal symptoms (EPS)

to assess resource utilization by frequency of divided by the patient's total number of days of study drug exposure for

to assess the longer term safety of olanzapine for up to 12 additional weeks of therapy

to assess the treatment of the core domains of BPD as assessed by LOCF mean change from baseline to endpoint in each of the four ZAN-BPD domain scores (cognitive disturbances,disturbed relationships,affective disturbances,and impulsivity)

as determined by the LOCF mean change from baseline to endpoint

or medical visits(emergency department, general and special care physicians, and other mental health care professionals

The frequency of suicide attempts for each patient will be calculated as the number of suicide attempts divided by the patient's total number of days of study drug exposure

to assess the reduction of aggression, suicidality, and irritability as measured by the LOCF mean change from baseline to endpoint in the rating of the Overt Aggression Scale-Modified (OAS-M) total score

as measured by TEAE, change in vital signs and laboratory analytes, ECG and severity of EPS.

or medical visits (emergency department, general and special care physicians or other mental health care professionals

The Simpson Angus Scale, Abnormal Involuntary Movement Scale and Barnes Akathisia Scale will be used to measure EPS

to evaluate the level of functioning as measured by LOCF mean change from baseline to endpoint on the Sheehan Disability Scale (Work, Social Life,and Family Life/Home Responsibilities)total score

to assess the following symptom domains (paranoid ideation, psychoticism, anxiety, depression, anger/hostility, interpersonal sensitivity, phobic anxiety, obsessive-compulsive, and somatization)on the Global Severity Index of the SCL-90-R

to assess the resource utilization by frequency divided by the patient's total number of days of study drug exposure for days hospitalized for physical and psychological reasons,number of hospital admissions

to evaluate the level of functioning in patients as measured by LOCF mean change from baseline to endpoint on the GAF

to assess the treatment of depressive mood symptoms as measured by LOCF mean change from baseline to endpoint in the total score on the Montgomery-Asberg Depression Rating Scale (MADRS)

The objectives of Study Period III (Open Label Extension Period are:

to evaluate the rate of response, time in response, and time to response. Levels of response are defined as a 30% and 50% reduction in the ZAN-BPD total score from baseline (Visit 2)

and individual scores(Work, Social Life,Family Life/Home Responsibilities, Days Lost, and Days Under Productive)

days hospitalized for physical and psychological reasons, number of hospital admissions

as measured by the ZAN-BPD total score, MADRS, Sheehan Disability Scale and LSDS

in improving overall symptomatology as measured by last observation carried forward (LOCF) mean change from baseline to endpoint in the ZAN-BPD total score for up to 12 weeks of double-blind treatment

The frequency of self-mutilation for each patient will be calculated as the number of self-mutilations divided by the patient's total number of study drug exposure

to assess the reduction of suicide attempts as determined by the mean frequency of suicide attempts.

to explore the efficacy of continued olanzapine treatment for up to 12 additional weeks of therapy

Secondary ID(s)

F1D-MC-HGKK

6253

Source(s) of Monetary Support

Please refer to primary and secondary sponsors